Profitability Metrics

Gross Margin
9.55%
Operating Margin
3.86%
Net Margin
2.27%

Efficiency Metrics

Revenue per Expense Ratio
1.04
R&D as % of Revenue
0.00%

Earnings Quality

EBITDA Margin
5.57%
Income Tax Rate
20.81%
EPS
1.8100000000

Balance Sheet Analysis

Current Ratio
2.29
Cash Ratio
0.40
Working Capital
$922.20M
Debt to Equity
0.44
Debt to Assets
20.65%
Equity Ratio
47.44%

Cash Flow Analysis

Operating Cash Flow Ratio
6.14%
Free Cash Flow Ratio
3.40%
CapEx to Revenue
2.74%
Dividends Paid
$23.46M
Stock Buybacks
$11.02M
Total Shareholder Returns
$34.47M
Cash Position Change
36.53%

Key Takeaways (2023 FY)

  • Revenue declined by 1.6406642204238%, indicating potential market challenges
  • Increased dividend payments by 0.19%

Detailed Growth Metrics

Core Performance

Revenue
-1.64%
Net Income
-5.74%
EPS
-6.70%
Operating Income
21.76%

Operational Efficiency

R&D Expenses
0.00%
SG&A Expenses
-2.12%
Operating Cash Flow
198.21%
Free Cash Flow
143.06%

Balance Sheet Health

Assets
2.13%
Debt
10.37%
Book Value per Share
3.99%
Inventory
-6.04%

Shareholder Returns

Dividends per Share
0.19%
Shares Outstanding
1.10%

Long Term Trends

3Y Revenue/Share
42.00%
5Y Revenue/Share
44.10%
3Y Dividend/Share
4.54%
5Y Dividend/Share
45.47%